Processing

Please wait...

Settings

Settings

Goto Application

1. BRPI0607486 - anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos.

Office Brazil
Application Number PI0607486
Application Date 03.03.2006
Publication Number PI0607486
Publication Date 04.08.2009
Grant Number PI0607486
Grant Date 16.04.2019
Publication Kind B1
IPC
A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
C12N 15/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
CPC
A61K 39/39558
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
39533against materials from animals
39558against tumor tissues, cells, antigens
A61K 47/6849
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6835the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
6849the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
A61K 51/1027
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
51Preparations containing radioactive substances for use in therapy or testing in vivo
02characterised by the carrier ; , i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
04Organic compounds
08Peptides, e.g. proteins ; , carriers being peptides, polyamino acids, proteins
10Antibodies or immunoglobulins; Fragments thereof ; , the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
1027against receptors, cell-surface antigens or cell-surface determinants
A61K 2039/505
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
A61K 2039/507
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
505comprising antibodies
507Comprising a combination of two or more separate antibodies
A61P 3/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
Applicants IMMUNOMEDICS, INC.
Inventors CHIEN-HSING CHANG
DAVID M. GOLDENBERG
HANS J. HANSEN
ZHENGXING QU
Agents DANNEMANN, SIEMSEN, BIGLER & IPANEMA MOREIRA
Priority Data 60/657,695 03.03.2005 US
Title
(PT) anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos.
Abstract
(PT)
anticorpo l243 humanizado, anticorpo biespecífico ou fragmentos de ligação a antígeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos. a presente invenção refere-se a anticorpos humanizados que especificamente ligam hla-dr. os anticorpos reconhecem o epitopo reconhecido pelo anticorpo monoclonal de camundongo l243. são providos processos para a preparação de tais anticorpos, composições farmacêuticas contendo tais anticorpos, e diagnóstico e terapêutico clínico, bem como usos relacionados com pesquisa para tais anticorpo.

Other related publications